Zydus Lifesciences Gets USFDA Approval for Generic Methylene Blue Injection
By Rediff Money Desk, NEWDELHI Dec 06, 2023 16:56
Zydus Lifesciences has received USFDA approval to market a generic version of ProvayBlue injection, a treatment for acquired methemoglobinemia. The company's vial presentation offers a cost-effective alternative.
![Zydus Lifesciences Gets USFDA Approval for Generic Methylene Blue Injection](https://im.rediff.com/money/2023/mar/31zydus.jpg)
Photograph: Courtesy Zydus.
New Delhi, Dec 6 (PTI) Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to market a generic product to treat a rare blood condition.
The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Methylene Blue injection in strengths of 10mg/2ml and 50mg/5ml, the drug firm said in a statement.
Zydus' product is the generic version of ProvayBlue injection.
The majority of current market usage is still on the ampoule presentation whereas Zydus is offering a generic version of Methylene Blue injection in vial presentation, the company stated.
From a hospital perspective, a vial presentation is an affordable option with significant benefits and advantages, it added.
Methylene Blue injection is an oxidation-reduction agent indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia.
As per IQVIA MAT data, Methylene Blue injection (10mg/2ml and 50mg/5ml) had an annual sale of around USD 73.4 million in the US.
The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Methylene Blue injection in strengths of 10mg/2ml and 50mg/5ml, the drug firm said in a statement.
Zydus' product is the generic version of ProvayBlue injection.
The majority of current market usage is still on the ampoule presentation whereas Zydus is offering a generic version of Methylene Blue injection in vial presentation, the company stated.
From a hospital perspective, a vial presentation is an affordable option with significant benefits and advantages, it added.
Methylene Blue injection is an oxidation-reduction agent indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia.
As per IQVIA MAT data, Methylene Blue injection (10mg/2ml and 50mg/5ml) had an annual sale of around USD 73.4 million in the US.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- GTL Infrastructure
- 2.93 ( -4.87)
- 226206286
- IFL Enterprises
- 1.30 (+ 4.84)
- 81461564
- Vodafone Idea L
- 16.79 (+ 0.66)
- 67447398
- NCL Research
- 0.95 ( -4.04)
- 31996628
- Franklin Industries
- 3.73 (+ 3.32)
- 21511209
MORE NEWS
![SBI 444-Day Term...](https://im.rediff.com/80-80/money/2017/aug/01bank.jpg)
SBI 444-Day Term Deposit: Up to 7.25% Annual...
State Bank of India launches a 444-day term deposit offering up to 7.25% annual...
![India To Set Up...](https://im.rediff.com/80-80/money/2020/sep/15business-2.jpg)
India To Set Up Centre For Trade Negotiation...
India's Commerce Ministry plans to establish a centre for negotiation skills to...
![Vi Improves...](https://im.rediff.com/80-80/money/2024/may/14may-vi.jpg)
Vi Improves Network Coverage in Uttarakhand & UP
Vi expands L900 & L2100 technologies in UP and Uttarakhand, offering improved indoor...